Pliant Therapeutics to Participate in Upcoming Investor Events

Core Insights - Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for fibrotic diseases [1][4] - The company will participate in several investor events in September 2024, including the Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference, and Stifel Virtual Immunology and Inflammation Summit [2] Company Overview - Pliant Therapeutics is recognized as a leader in the discovery and development of therapeutics for fibrotic diseases [4] - The lead product candidate, bexotegrast (PLN74809), is an oral small molecule that acts as a dual selective inhibitor of αvß6 and αvß1 integrins, targeting idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) [4] - Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the FDA for both IPF and PSC, as well as Orphan Drug Designation from the European Medicines Agency [4] - Pliant has initiated the BEACON-IPF trial, an adaptive Phase 2b/3 study for bexotegrast in IPF [4] - The company is also conducting a Phase 1 study for PLN-101095, a small molecule targeting solid tumors, and has received regulatory clearance for a Phase 1 study of PLN-101325, a monoclonal antibody for muscular dystrophies [4]